1. Proceedings
  2. I3M
  3. 2022
  4. EMSS
  5. 10.46354/i3m.2022.emss.001

The Expected Value of Perfect Information of COVID-19 Treatment Using Discrete Event Simulation

  • Doraid Dalalah 
  • Industrial Engineering and Engineering Management, University of Sharjah, Sharjah, United Arab Emirates
Cite as
Dalalah D. (2022).,The Expected Value of Perfect Information of COVID-19 Treatment Using Discrete Event Simulation. Proceedings of the 34th European Modeling & Simulation Symposium (EMSS 2022). , 001 . DOI: https://doi.org/10.46354/i3m.2022.emss.001

Abstract

The Value of Perfect Information (EVPI) and also Sample Information (EVSI) are necessary for calculating the expected economic benefit of a research based on evidence about the cost and efficacy of novel therapies. The EVPI determines the maximum value resulting from soliciting data to decrease the uncertainties and the expected loss in case of providing ineffective treatment. In general, an inefficient decision will waste health resources that may be better spent elsewhere, thereby deteriorating health outcomes. In this article, the value of information resulting from reducing uncertainty will be applied in assessing two COVID-19 treatments, namely, the standard care and vaccines. A discrete event simulation model is introduced to expand the usage of EVPI calculations to medical applications with various sources of uncertainty as the case of COVID-19. Our simulation results show that further testing and vaccine validation will be of insignificant value if the response rate on vaccine is higher than 85%. The purpose of this study is to provide a step-by-step guide to the computation of the value pre-testing in the context of healthcare decision-making. Worked scenarios were presented for COVID-19 in UAE. The study can serve as a useful template for various decision-making problems in medical settings.

References

  1. Constantinou B. Yet, A., N. Fenton and M. Neil, "Expected Value of Partial Perfect Information in Hybrid Models Using Dynamic Discretization," in IEEE Access, vol. 6, pp. 7802-7817, 2018.
  2. Hisrael Passarelli-Araujo, Henrique Pott-Junior, Aline M. Susuki, André S. Olak, Rodrigo R. Pescim, Maria F.A.I. Tomimatsu, Cilio J. Volce, Maria A.Z. Neves, Fernanda F. Silva, Simone G. Narciso, Michael Aschner, Monica M.B. Paoliello, Mariana R. Urbano, (2022). The impact of COVID-19 vaccination on  case fatality rates in a city in Southern Brazil, American Journal of Infection Control, In press. https://doi.org/10.1016/j.ajic.2022.02.015
  3. Hotez PJ, Bottazzi ME (2020) Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis 14(7): e0008548.
  4. Marta Caserotti, Teresa Gavaruzzi, Paolo Girardi, Alessandra Tasso, Chiara Buizza, Valentina Candini, Cristina Zarbo, Flavia Chiarotti, Sonia Brescianini, Gemma Calamandrei, Fabrizio Starace, Giovanni de Girolamo, Lorella Lotto, (2022). Who is likely to vacillate in their COVID-19 vaccination decision? Free-riding intention and post-positive reluctance, Preventive Medicine, Volume 154, 2022, 106885.
  5. Meredith G. Hosek, Autumn B. Chidester, Jonathan Gelfond, Barbara S. Taylor, (2022). Low Prevalence of COVID-19 Vaccine Hesitancy in Students Across Health Science Disciplines in Texas, Vaccine: X, Volume 10, 100154.
  6. Merkley Eric, Peter John Loewen, (2022). The correlates and dynamics of COVID-19 vaccinespecific hesitancy, Vaccine, Volume 40, Issue 13, Pages 2020-2027.
  7. Michele Kohli, Michael Maschio, Debbie Becker, Milton C. Weinstein, (2021). The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of costeffectiveness modeling to inform vaccination prioritization, Vaccine, Volume 39, Issue 7, Pages 1157-1164.
  8. Sizhong Sun, (2022). The Demand for A COVID-19 Vaccine, Economics & Human Biology, 101135.
  9. Sookaromdee, P., & Wiwanitkit, V. (2021). New COVID- 19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis. Archives of medical research, 52(4), 453.
  10. Sylvia H. Hsu, Su-Hsin Chang, Cary P. Gross, Shi-Yi Wang, 2021. Relative risks of COVID-19 fatality between the first and second waves of the pandemic in Ontario, Canada, International Journal of Infectious Diseases, Volume 109, Pages 189-191.
  11. Timelli Laura, Giuseppina Liuzzi, Alessandro Cannavacciuolo, Nicola Petrosillo, Vincenzo Puro, Enrico Girardi, (2021). Association of COVID-19 case fatality rate with disease burden: an ecological analysis in Italy during the first wave, International Journal of Infectious Diseases, Volume 111, Pages 186-189.
  12. WHO, COVID-19 Weekly Epidemiological Update Edition 75, published 18 January 2022.
  13. Winter T., B.C. Riordan, D. Scarf, P.E. Jose, (2022). Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically rightwing citizens, Vaccine, Volume 40, Issue 12, 2022, Pages 1896-1903.